Sienna Cancer Diagnostics Ltd. announced the appointment of Scientle Innovations (Scientle) as its exclusive distributor in New Zealand. The distribution agreement provides Scientle with the right to sell Sienna's hTERT IVD to pathology laboratories where it will be used to assist in the diagnosis of bladder cancer. This agreement with Scientle marks the 10th country in which Sienna has secured a distribution agreement and partner for hTERT to be sold to pathology laboratories as an adjunct test in the diagnosis of bladder cancer. In addition to providing regulatory support, sales, marketing and technical training to Scientle staff, Sienna will work with Scientle to establish hTERT in several reference laboratories to assist in the adoption of the test in New Zealand. Scientle and Sienna are monitoring the restrictions due to the current COVID-19 pandemic. As soon as travel restrictions are lifted between Australia and New Zealand, work will commence on establishing these reference sites.